UCB invites scientists to access its new cutting-edge technology platform
The UK subsidiary of Belgium’s leading pharma company UCB (Euronext Brussels: UCB), which at the end of last year completed a $5.5 million investment in a new laboratory with cutting edge robotic equipment for the fully automated discovery of antibodies, today launched its “Technology Platform Access,” a collaboration program for the discovery and development of novel antibodies against potential therapeutic targets.
Commenting on the new program, Ismail Kola, executive vice president, UCB NewMedicines, said: “Partnerships between academic groups and industry are vital to the future of scientific discovery. We are hugely committed to seeking new ways of working and creating super-networks to advance medical research and improve health.” He added, “This program offers the chance for groups to access our state-of-the-art technology as well as collaborate with our premier discovery team.”
Ready to also cooperate with biotech firms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze